Molecular imaging of αvβ3 expression in cancer patients

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 3, 2010, Pages 309-326

  Gaertner, F C ^a   Schwaiger, M ^a   Beer, A J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alph v beta 3; Angiogenesis; Integrins; Molecular imaging; Positron emission tomography; Tomography, emission computed, single photon

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID ARGINYLGLYCYLASPARTIC ACID GA 68; AH 111585; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID K5 F18; BEVACIZUMAB; BIOLOGICAL MARKER; FLUCICLATIDE F18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GALACTOARGINYLGLYCYLASPARTIC ACID F 18; GALLIUM 68; NC 100692; OXALIPLATIN; RADIOISOTOPE; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BINDING AFFINITY; BLOOD VESSEL PERMEABILITY; BLOOD VOLUME; BREAST CANCER; CANCER PATIENT; CANCER SCREENING; COLORECTAL CANCER; DOSIMETRY; DRUG DISTRIBUTION; DRUG TARGETING; HUMAN; IN VIVO STUDY; LIVER METASTASIS; LUNG CANCER; METASTASIS; MOLECULAR IMAGING; NEOPLASM; NONHUMAN; PATIENT CODING; PHOTON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN EXPRESSION; RADIATION EXPOSURE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR BLOOD FLOW;

BREAST NEOPLASMS; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; MELANOMA; MOLECULAR IMAGING; NEOPLASM STAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR MICROENVIRONMENT;

EID: 77958592746     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. Nov 18 1971;285:1182-6.
2. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
3. Folkman J, Kalluri R. Cancer without disease. Nature 2004;427:1.
4. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006;312:1171-5.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
6. Galbraith SM. Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development. Br J Radiol 2003;76 Spec No 1:S83-86.
7. Marcus CD, Ladam-Marcus V, Cucu C, Bouche O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009;72:217-38.
8. Takada Y, Ye X, Simon S. The integrins. Genome Biol 2007;8:215.
9. Contois L, Akalu A, Brooks PC. Integrins as "functional hubs" in the regulation of pathological angiogenesis. Seminars in Cancer Biology 2009;19:318-28.
10. Rathinam R, Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev 2010;29:223-37.
11. Hynes RO, Bader BL, Hodivala-Dilke K. Integrins in vascular development. Braz J Med Biol Res 1999;32:501-10.
12. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008;49 Suppl 2:113S-128S.
13. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA 2005;293:855-62.
14. Matsumoto K, Kitamura K, Mizuta T, Tanaka K, Yamamoto S, Sakamoto S et al. Performance characteristics of a new 3-dimensional continuous-emission and spiral-transmission high-sensitivity and high-resolution PET camera evaluated with the NEMA NU 2-2001 standard. J Nucl Med 2006;47:83-90.
15. Chatziioannou AF. Instrumentation for molecular imaging in pre-clinical research: Micro-PET and Micro-SPECT. Proc Am Thorac Soc 2005;2:533-6, 510-1.
16. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987;238:491-7.
17. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer; 10:9-22.
18. Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E, Milonakis A, Sirmalis G et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med 1998;25.1383-9.
19. Hua J, Dobrucki LW, Sadeghi MM, et al. Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation. Jun 21 2005;111(24):3255-3260.
20. Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC 100692. J Nucl Med 2006;47:1434-9.
21. Bach-Gansmo T, Bogsrud TV, Skretting A. Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labeiled NC100692. Clin Physiol Funct Imagine 2008;28:235-9.
22. Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol 2010;51:40-6.
23. Gurrath M, Muller G, Kessler H, Aumailley M, Timpl R. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem 1992;210:911-21.
24. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991;291:50-4.
25. Haubner RH, Wester HJ, Weber WA, Schwaiger M. Radiotracer-based strategies to image angiogenesis. Q J Nucl Med 2003;47:189-99.
26. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999;40:1061-71.
27. Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry 2003;9:2717-25.
28. Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G et al. Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J Nucl Med 2004;45:892-902.
29. Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 2004;31:1081-9.
30. Chen X, Park R, Shahinian AH, Bading JR, Conti PS. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 2004;31:11-9.
31. Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med 2004;45:1776-83.
32. Schottelius M, Wester HJ, Reubi JC, Senekowitsch-Schmidtke R, Schwaiger M. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. Bioconjug Chem 2002;13:1021-30.
33. Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur J Nucl Med Mol Imaging 2002;29:28-38.
34. Wester HJ, Schottelius M, Poethko T, Bruus-Jensen K, Schwaiger M. Radiolabeled carbohydrated somatostatin analogs: a review of the current status. Cancer Biother Radiopharm 2004;19:231-44.
35. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-36.
36. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 1 2001;61:1781-5.
37. Ziegler SI, Pichler BJ, Boening G, Rafecas M, Pimpl W, Lorenz E et al. A prototype high-resolution animal positron tomograph with avalanche photodiode arrays and LSO crystals. Eur J Nucl Med 2001;28:136-43.
38. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005;2.e70.
39. Myoken Y, Kayada Y, Okamoto T, Kan M, Sato GH, Sato JD. Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Proc Natl Acad Sci U S A 1991;88:5819-23.
40. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004;15:61-9.
41. Janssen M, Oyen WJ, Massuger LF, Frielink C, Dijkgraaf I, Edwards DS et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 2002;17:641-6.
42. Chen X, Tohme M, Park R, Hou Y, Bading JR, Conti PS. Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 2004;3:96-104.
43. Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 2004;6:350-9.
44. Pichler BJ, Kneilling M, Haubner R, Braumüller H, Schwaiger M, Röcken M et al. Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. J Nucl Med 2005;46:184-9.
45. Beer AJ, Schwaiger M. [Molecular imaging with new PET tracers]. Radiologe an 2007;47:8-17.
46. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in viva high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.
47. Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 2009;251:166-74.
48. Icrp. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP 2008;38:1-197.
49. Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 2006;47:763-9.
50. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005;46:1333-41.
51. McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002;1:459-65.
52. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999;18:345-57.
53. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006;12:3942-9.
54. Zhang ZJ, Chen JH, Meng L, Du JJ, Zhang L, Liu Y et al. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer. Chin Med J (Engl) 2007;120:125-31.
55. Higashi K, Ito K, Hiramatsu Y, Ishikawa T, Sakuma T, Matsunari I et al. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med 2005;46:267-73.
56. Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004;31:1621-30.
57. Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ et al. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med 2008;49:22-9.
58. Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 2006,8:R20.
59. Liapis H, Flath A, Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 1996;5:127-35.
60. Nakamura I, Pilkington MF, Lakkakorpi PT, Lipfert L, Sims SM, Dixon SJ et al. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. J Cell Sci 1999;112(Pt 22):3985-93.
61. Metz S, Ganter C, Rummeny EJ, Brix G, Schwaiger M, Beer AJ. Characterization of Tumor Biology with MRI and PET: Relationship between Microcirculation, Integrin (v®3 Expression, and Glucose Metabolism. RSNA (abstract) 2009.
62. Zatterstrom UK, Brun E, Willen R, Kjellen E, Wennerberg J. Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck. Head Neck 1995;17:312-8.
63. O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 2001;92:556-68.
64. Erovic BM, Neuchrist C, Berger U, El-Rabadi K, Burian M. Quantitation of microvessel density in squamous cell carcinoma of the head and neck by computer-aided image analysis. Wien Klin Wochenschr 2005;117:53-7.
65. Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. Nov 15 2007;13(22 Pt 1):6610-6.
66. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003;20:203-13.
67. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:9482-7.
68. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96:1815-22.
69. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002;62:4263-72.
70. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY et al. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998;4:2625-34.
71. Berry MG, Gui GP, Wells CA, Carpenter R. Integrin expression and survival in human breast cancer. Eur J Surg Oncol 2004;30:484-9.
72. Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P et al. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008;49:255-9.
73. Stangier I, Wester HJ, Schwaiger M, Beer AJ. Comparison of standardised uptake values and distribution volume for imaging of (v®3 expression in breast cancer patients with [18F]Galacto-RGD PET. J Nucl Med 2007;48(Supplement 2):406.
74. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ et al. Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 2008;18:378-86.
75. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007;25:1651-7.
76. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 2008;17:1225-35.
77. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol 2009;11:861-70.
78. Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008;49:879-86.
79. McParland BJ, Miller MP, Spinks TJ, Kenny LM, Osman S, Khela MK et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. J Nucl Med 2008;49:1664-7.
80. Winick J. A Proof-of-Concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis. ClinicalTrials.gov. November 28, 2007 edition U.S. National Institutes of Health; 2007.
81. Jeong JM, Hong MK, Chang YS, Lee YS, Kim YJ, Cheon GJ et al. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)- isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008;49:830-6.
82. Fanti S, Farsad M, Mansi L. PET-CT Beyond FDG: A Quick Guide to Image Interpretation. 1st Edition ed. Berlin: Springer-Verlag; 2010.
83. Kolb H, Walsh J, Liang Q, Zhao T, Gao D, Secrest J. 18F-RGD-K5: A cyclic triazole-bearing RGD peptide for imaging integrin 〈v®3 expression in vivo. J Nucl Med 2009;50(Supplement 2):329.
84. Cho HJ, Lee DL, Park JY et al. First in human evaluation of a newly developed PET tracer, 18F-RGD-K5 in patients with breast cancer: Comparison with 18F-FDG uptake pattern and microvessel density. J Nucl Med 2009;50(Supplement 2):1910.
85. Doss M, Alpaugh RK, Yu JQ. Biodistribution and radiation dosimetry of angiogenesis marker [18F]RGD-K5 measured using human PET. J Nucl Med 2009;50(Supplement 2):447.
86. Zhang J. Efficacy study of [18F]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug (K5-101). ClinicalTrials.gov. October 1, 2009 ed: U.S. National Institutes of Health; 2009.
87. Wu Z, Li ZB, Cai W, He L, Chin FT, Li F et al. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2007;34:1823-31.
88. Liu S, Liu Z, Chen K, Yan Y, Watzlowik P, Wester HJ et al. (18)F-Labeled Galacto and PEGylated RGD Dimers for PET Imaging of alpha(v)beta (3) Integrin Expression. Mol Imaging Biol Dec 1 2009 [Epub ahead of print].
89. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
90. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002;8:918-21.
91. Blystone SD, Slater SE, Williams MP, Crow MT, Brown EJ. A molecular mechanism of integrin crosstalk: alphavbeta3 suppression of calcium/calmodulin- dependent protein kinase II regulates alpha5beta1 function. J Cell Biol 1999;145:889-97.
92. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med Jan;8:27-34.
93. Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, Wedge SR. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med 2009;50:116-22.
94. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001;98:1853-8.
95. Byzova TV, Kim W, Midura RJ, Plow EF. Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp Cell Res 2000;254:299-308.
96. Stupack DG, Cheresh DA. A Bit-role for integrins in apoptosis. Nat Cell Biol 2004;6:388-9.
97. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26:5610-7.
98. Chen X, Sievers E, Hou Y, Park R, Tohme M, Bart R et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia 2005;7:271-9.
99. Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 2008;14:459-65.